Becton, Dickinson and Company (LON:0R19)
193.71
+3.95 (2.08%)
At close: Oct 3, 2025
LON:0R19 Revenue
Becton, Dickinson and Company had revenue of $5.51B USD in the quarter ending June 30, 2025, with 10.40% growth. This brings the company's revenue in the last twelve months to $21.39B, up 7.86% year-over-year. In the fiscal year ending September 30, 2024, Becton, Dickinson and Company had annual revenue of $20.18B with 4.16% growth.
Revenue (ttm)
$21.39B
Revenue Growth
+7.86%
P/S Ratio
2.64
Revenue / Employee
$289.00K
Employees
74,000
Market Cap
41.18B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 20.18B | 806.00M | 4.16% |
Sep 30, 2023 | 19.37B | 502.00M | 2.66% |
Sep 30, 2022 | 18.87B | -261.00M | -1.36% |
Sep 30, 2021 | 19.13B | 3.06B | 19.02% |
Sep 30, 2020 | 16.07B | -1.22B | -7.03% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Becton, Dickinson and Company News
- 7 days ago - Best Dividend Aristocrats For October 2025 - Seeking Alpha
- 13 days ago - Becton Dickinson (BDX) Partners with Henry Ford Health for Pharmacy Automation - GuruFocus
- 13 days ago - BD and Henry Ford Health Sign Pharmacy Automation Partnership to Revolutionize Medication Storage and Prescription Delivery - PRNewsWire
- 15 days ago - BDX Quantitative Stock Analysis - Peter Lynch - Nasdaq
- 16 days ago - Fluorescence Cell Market Forecasts USD 6.37 Billion by 2034 at 7.29% CAGR - GlobeNewsWire
- 17 days ago - Becton, Dickinson and Company (BDX) Secures $2.75 Billion Revolving Credit Facility - GuruFocus
- 18 days ago - BD Marks 1,000th BD Rhapsody System, Driving Scientific Breakthroughs via Single-Cell Multiomics - PRNewsWire
- 20 days ago - BD (BDX) Expands Alaris Pump Recall, Adds 15 More Infusion Sets - GuruFocus